Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Desloratadine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Desloratadine. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-000358-65 Sponsor Protocol Number: A00394 Start Date*: 2005-11-21
    Sponsor Name:UCB Pharma S.A.
    Full Title: A multicentre, double-blind, two parallel groups, randomized trial over four weeks of treatment to compare the clinical efficacy and safety of Levocetirizine 5 mg oral capsules once daily in the mo...
    Medical condition: Chronic Idiopathic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    8.0 10009159 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-006133-32 Sponsor Protocol Number: P04685 Start Date*: 2006-09-20
    Sponsor Name:Allergie-Centrum-Charité
    Full Title: An exploratory phase IV, randomised, double-blind, placebo controlled crossover study to assess and compare the effects of 5 mg vs. 20 mg Desloratadine on the development of experimentally induced ...
    Medical condition: Acquired cold urticaria (ACU) is a frequent form of physical urticaria that is characterized by the development of wheal and flare type skin reactions after cold exposure.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046741 Urticaria cold LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003686-13 Sponsor Protocol Number: P04805-V2.0 Start Date*: 2007-05-31
    Sponsor Name:Allergie-Centrum-Charite, Department of Dermatology, Charite - Universitätsmedizin Berlin
    Full Title: An exploratory phase III, randomised, double blind, therapeutic single dose-related effect, parallel group study to assess and compare the effects of 5mg vs. 20mg Desloratadine on skin lesions in p...
    Medical condition: Chronic urticaria is characterized by the spontaneous development of wheal and flare type skin reactions.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009159 Chronic urticaria LLT
    9.1 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002823-42 Sponsor Protocol Number: A00401 Start Date*: 2005-05-02
    Sponsor Name:UCB S.A. Pharma Sector
    Full Title: A multicentre, double-blind, parallel, randomized, placebo-controlled study : Evaluation of the efficacy and safety of Levocetirizine 5 mg and Desloratadine 5 mg administered orally as capsules onc...
    Medical condition: Allergic Rhinitis (AR)
    Disease: Version SOC Term Classification Code Term Level
    7.1 10001723 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005746-22 Sponsor Protocol Number: AECUDATT Start Date*: 2009-05-05
    Sponsor Name:Allergie-Centrum-Charite, Department of Dermatology, Charite - Universitätsmedizin Berlin
    Full Title: Multi-center, double blind, dose escalating study to compare the effects of 5 mg, 10mg and 20mg of Desloratadine in patients with acquired cold urticaria (ACU)
    Medical condition: Chronic urticaria is characterized by the spontaneous development of wheal and flare type skin reactions.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009869 Cold urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001860-36 Sponsor Protocol Number: V00114CP3042A Start Date*: 2008-05-29
    Sponsor Name:Pierre Fabre Médicament
    Full Title: EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CO...
    Medical condition: The medical condition to be investigated in this study is the seasonall allergic rhinitis. The intendent indication for the product is the treatment of allergic rhinitis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-004002-10 Sponsor Protocol Number: UFD-DESIC-001 Start Date*: 2012-12-10
    Sponsor Name:Department of Dermatology and Allergology, University of Szeged
    Full Title: Comparison of the effectiveness of desloratadine monotherapy and the combined cinnarizine and iprazochrome therapy for the treatment of urticaria factitia
    Medical condition: Among physical urticaria patients about 20-30% have urticaria factitia. The pathomechanism of urticaria factitia is not clear. Antihistamines are used to treat the condition, and this is in accorda...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005450-45 Sponsor Protocol Number: P04684 Start Date*: 2006-08-30
    Sponsor Name:Schering-Plough Research Institute
    Full Title: Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/ Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Mee...
    Medical condition: Persistent Allergic Rhinitis (Allergic Rhinitis)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039085 PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PT (Completed) ES (Completed) DE (Completed) HU (Completed) SE (Completed) GR (Completed) DK (Completed) IT (Completed) BE (Completed) NL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-001449-33 Sponsor Protocol Number: PO4849 Start Date*: 2007-07-18
    Sponsor Name:Schering Plough Research Institute (SPRI), A Division of Schering Corporation
    Full Title: A study of the efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with AERIUS Tablets (5 mg, 10 mg, or 20 mg once daily).
    Medical condition: Subjects with an active episode of chronic idiopathic urticaria (CIU) and are taking a second-generation antihistamine will be selected for the study. The urticaria activity score (UAS) must be be...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10021247 Idiopathic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed) SK (Completed) SE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005449-20 Sponsor Protocol Number: P04683 Start Date*: 2006-08-30
    Sponsor Name:Schering-Plough Research Institute
    Full Title: Double-Blind, Randomized, Placebo-Controlled, Parallel-Groups, Multicenter/ Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis who Me...
    Medical condition: Intermittent Allergic Rhinitis (Allergic Rhinitis)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039085 PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PT (Completed) ES (Completed) DE (Completed) HU (Completed) SE (Completed) GR (Completed) DK (Completed) IT (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-004821-15 Sponsor Protocol Number: TT-04 Start Date*: 2016-03-18
    Sponsor Name:ALK Abello A/S
    Full Title: Efficacy and safety of the SQ tree SLIT-tablet in subjects with moderate to severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch group
    Medical condition: Allergic Rhinoconjunctivitis induced by birch pollen
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) CZ (Completed) FI (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-000790-13 Sponsor Protocol Number: BIL-0115-MED Start Date*: 2015-06-10
    Sponsor Name:FAES FARMA, S.A.
    Full Title: A single-centre, randomized, double-blind, crossover, single-dose clinical trial to compare bilastine, desloratadine, rupatadine and placebo in the suppression of wheal and flare induced by intrade...
    Medical condition: ALLERGIC RHINOCONJUNTIVITIS AND CHRONIC URTICARIA
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000133-22 Sponsor Protocol Number: V00114 CP 304 2A Start Date*: 2008-04-28
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Estudio de la eficacia y seguridad del antihistamínico V0114CP 2.5 mg en el tratamiento de la rinitis alérgica estacional. Estudio aleatorizado, doble ciego, de tres ramas y grupos paralelos, que i...
    Medical condition: Demostrar la eficacia de un tratamiento de 2 semanas con el antihistamínico V0114CP 2,5 mg frente a placebo en la reducción de síntomas de la rinitis alérgica estacional
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) EE (Completed) BE (Completed) LT (Completed) PL (Completed) HU (Completed) DE (Completed) IT (Completed) BG (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2004-002971-18 Sponsor Protocol Number: A00391 Start Date*: 2005-04-29
    Sponsor Name:UCB S.A. Pharma Sector
    Full Title: A monocenter, double-blind, randomized trial, with two parallel groups comparing the clinical efficacy of levocetirizine 5 mg capsules and desloratadine 5 mg capsules taken once a day over 3 weeks ...
    Medical condition: Adult subjects suffering from seasonal allergic rhinitis (SAR) due to grass pollen
    Disease: Version SOC Term Classification Code Term Level
    7.1 10039776 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001883-39 Sponsor Protocol Number: P02561 Start Date*: 2004-09-21
    Sponsor Name:Schering Plough Reserach Institute
    Full Title: Study to Evaluate the Effect of the Coadministration of SCH 497079 (a Histamine 3 [H3] Receptor Antagonist) Plus Desloratadine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis Who Ha...
    Medical condition: Seasonal Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10039776 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003593-18 Sponsor Protocol Number: GT-19 Start Date*: 2008-09-04
    Sponsor Name:ALK-Abelló A/S
    Full Title: A Phase III trial evaluating the tolerability of Grazax treatment in combination with antihistamine in subjects with seasonal grass pollen induced rhinoconjunctivitis
    Medical condition: Grass pollen induced rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023057-11 Sponsor Protocol Number: DC02/RUP/3/09 Start Date*: 2011-02-09
    Sponsor Name:J. Uriach y Compañía, S.A.
    Full Title: Efficacy and safety of rupatadine solution in the treatment of Chronic Spontaneous Urticaria (CSU) in paediatric patients (2-11 years old).
    Medical condition: Treatment of Chronic Spontaneous Urticaria (CSU) in paediatric patients (2-11 years old).
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10009159 Chronic urticaria LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004900-37 Sponsor Protocol Number: DC05/RUP/I/13 Start Date*: 2012-11-20
    Sponsor Name:J. Uriach y Compañía, S.A.
    Full Title: A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel group study to assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of oral Rupatadine in Healthy Japanese Subjec...
    Medical condition: This is a Phase I study in helathy subjects. No condition is being treated. The IMP is approved for symptomatic treatment of allergic rhinitis and urticaria in adults and adolescents (over 12 yea...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000608-13 Sponsor Protocol Number: MK-4117-201 Start Date*: 2017-02-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A phase III multicentre, parallel-group, randomized, placebo-controlled, double-blind clinical trial to study the efficacy and safety of MK-4117 in Japanese subjects with chronic urticaria.
    Medical condition: Chronic urticaria (a skin condition caused by an allergy)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10052568 Urticaria chronic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000186-76 Sponsor Protocol Number: MK-4117-200 Start Date*: 2017-01-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects with Perennial Allergic Rhinitis.
    Medical condition: Perennial allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 13:07:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA